Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 990 across all filing types
Latest filing 2025-08-28 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "浙江泰林生物技术股份有限公司2025 年半年度报告全文" which translates to "Zhejiang Tailin Bioengineering Co., Ltd. 2025 Semi-Annual Report Full Text." It explicitly states it is a half-year report covering the period from January 2025 to June 2025. The content includes detailed financial data, management discussion and analysis, business overview, product lines, and other substantive financial and operational information. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The document contains actual financial statements and detailed analysis, not just a notice or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-28 Chinese
关于2025年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage and usage of funds raised by Zhejiang Tailin Biotechnology Co., Ltd. during the first half of 2025. It includes specifics on the amounts raised through IPO and convertible bonds, the management and storage of these funds, usage details, changes in investment projects, and compliance with regulatory requirements. The document references regulatory approvals from the China Securities Regulatory Commission and Shenzhen Stock Exchange guidelines, and contains financial tables and explanations about the investment projects funded by the raised capital. The content is focused on the use and management of fundraising proceeds rather than general financial performance or earnings. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is sufficient and contains substantive financial data related to fundraising usage, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2025-08-28 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the eighth meeting of the fourth Supervisory Board of Zhejiang Tailin Biotechnology Co., Ltd. It includes approvals of the 2025 semi-annual report, a special report on the use of raised funds, a profit distribution plan, and amendments to the company charter. The document states that the full reports and details are published on the official disclosure website, indicating this document itself is an announcement of meeting resolutions rather than the full reports. The document length is short (1686 characters) and it references that the full reports are available elsewhere. This fits the profile of a Regulatory Filing (RNS) as it is a regulatory announcement of meeting resolutions and approvals, not the full financial or management reports themselves.
2025-08-28 Chinese
重大资产管理制度
Governance Information Classification · 95% confidence The document is titled as a "重大资产管理制度" which translates to "Major Asset Management System" for Zhejiang Tailin Biotechnology Co., Ltd. It outlines governance procedures, decision-making authority, and approval thresholds related to major asset transactions, bank borrowings, asset sales, and guarantees. The content is focused on internal governance rules and procedures rather than financial results, audit opinions, or shareholder meeting materials. It does not contain financial statements or earnings data, nor is it a report or announcement of voting results. It is a governance-related document detailing internal company rules and board authority regarding major asset management. Therefore, it fits best under Governance Information (CGR). The document length is 2421 characters, which is relatively short but contains substantive governance content, not just an announcement or notice. Hence, it is not RPA or RNS.
2025-08-28 Chinese
信息披露暂缓与豁免管理制度
Governance Information Classification · 95% confidence The document is a company internal policy titled 'Information Disclosure Delay and Exemption Management System' for Zhejiang Tailin Biotechnology Co., Ltd. It outlines rules and procedures for delaying or exempting disclosure of certain information, including references to relevant laws and stock exchange regulations. It is a governance or compliance-related document rather than a financial report, announcement, or regulatory filing. It does not contain financial data, voting results, or executive changes. It is not a report publication announcement or certification. Therefore, it fits best under Governance Information (CGR), which covers company internal rules and governance practices.
2025-08-28 Chinese
内部审计制度
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Audit System" for Zhejiang Tailin Biotechnology Co., Ltd. It details the internal audit policies, principles, organizational structure, responsibilities, procedures, and archival management. It references relevant laws and regulations, the company's articles of association, and the Shenzhen Stock Exchange rules. The content is a comprehensive internal audit policy document rather than a standalone audit report or financial statement. It does not contain financial data or audit results but rather the framework and rules governing internal audit activities within the company. Therefore, it is best classified as an Audit Report / Information (AR) type, which includes applied accounting principles and internal audit regulations, excluding full annual reports or financial statements.
2025-08-28 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.